This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Loser

Pharmacyclics Incorporated (PCYC) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.9%. By the end of trading, Pharmacyclics Incorporated fell $1.46 (-2.7%) to $53.05 on average volume. Throughout the day, 1.3 million shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in price between $51.38-$54.21 after having opened the day at $52.93 as compared to the previous trading day's close of $54.51. Other company's within the Drugs industry that declined today were: K-V Pharmaceutical Company (KV.B), down 21.2%, Reliv' International (RELV), down 13.6%, Ampio Pharmaceuticals (AMPE), down 12.3%, and ACADIA Pharmaceuticals (ACAD), down 8.5%.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $3.65 billion and is part of the health care sector. The company has a P/E ratio of 240.3, below the average drugs industry P/E ratio of 264.4 and above the S&P 500 P/E ratio of 17.7. Shares are up 256.7% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, premium valuation and weak operating cash flow.

On the positive front, Opexa Therapeutics (OPXA), up 86%, Cormedix (CRMD), up 19.1%, Affymax (AFFY), up 15.8%, and Cell Therapeutics (CTIC), up 12.4%, were all gainers within the drugs industry with Pfizer (PFE) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs